SUMMARY We have studied the secretin-pancreozymin stimulation test of pancreatic function with particular regard to its usefulness in the diagnosis of cystic fibrosis patients without gastrointestinal symptoms. We have compared the test results in 38 control individuals, 14 patients with cystic fibrosis and five other patients with problems affecting pancreatic function. Of the cystic fibrosis patients tested, six had no gastrointestinal symptoms and were shown to have normal or raised output of pancreatic enzymes measured (lipase, trypsin, chymotrypsin, and amylase). There was a positive correlation between both volume and bicarbonate measurement versus body weight in all subjects, but this relationship was clearly different in the cystic fibrosis patients compared with others regardless of the cystic fibrosis patients' ability to secrete pancreatic enzymes. Among the cystic fibrosis patients, bicarbonate concentration tended to be higher in those able to secrete a significant amount of pancreatic enzymes. However, the actual output of bicarbonate measured in all cystic fibrosis patients (range 0001-0.037 mmolIkg/45 min post-stimulation) was below that found in all control patients (range 0. 104-0.516 mmollkg/45 min post-stimulation). Therefore the secretin-pancreozymin test of pancreatic function appears to be useful in the diagnosis of cystic fibrosis even in those patients with adequate enzyme production.
We have evaluated the secretin-pancreozymin stimulation test of pancreatic function with regard to its usefulness in the diagnosis of cystic fibrosis. Difficulty in performing the test plus the high proportion (approximately 15%) of cystic fibrosis patients with normal or high pancreatic enzyme output has in the past severely limited its value for this purpose. It has been suggested, however, that even those cystic fibrosis patients with 'normal' enzyme output may have significantly decreased pancreatic bicarbonate and fluid secretion. Three patients (A-C) had Shwachman's syndrome, with neutropenia, recurrent infections, and growth failure. Patient A died at 3 months of age from fulminating infection. Only patient C had metaphyseal dysostosis. Patients B and C were mildly mentally retarded.
Two patients (D, E) had intractable diarrhoea of infancy. Examination of their small bowel mucosa showed extensive severe damage of unknown aetiology. In view of the nature and extent of the mucosal damage, it was felt likely that there might be secondary deficiency of small intestinal hormones and/or enzymes, including enterokinase.
The 38 'control' patients were tested in the course of investigation for a variety of complaints, such as chronic diarrhoea, recurrent abdominal pain, failure to thrive. These after a full evaluation were felt to be unrelated to pancreatic dysfunction.
Patients A-E and all controls had negative sweat tests (sodium and chloride less than 50 mmol/l). The age and weight of the three groups tested were comparable with the exception of the older cystic fibrosis patients (nos. 8, 9, 10, and 13).
PROCEDURES
The secretin-pancreozymin stimulation test was performed according to the method described by Delachaume-Salem and Sarles. 13 After a six to eight hour fast, a double lumen Salem Sump tube was passed into the third part of the duodenum and position confirmed by fluoroscopy. Duodenal secretions were aspirated for a 15 minute baseline period, and then for three consecutive 15 minute periods after intravenous secretin (Boots) 1 unit/kg and pancreozymin-cholecystokinin (Boots) 3 units/ kg, given immediately one after the other.
Volume and pH were noted for each specimen, and concentrations of bicarbonate, lipase, trypsin, chymotrypsin were determined as previously described. 13 Pancreatic enzyme results fell into two groups in the cystic fibrosis patients, demonstrating the expected divergence between those with gastrointestinal symptoms who have very low enzyme values (nos. 1-8) and those without whose enzyme results were well within the control range (nos. 9-12). All enzymes behaved similarly within each of the groups of cystic fibrosis patients and controls. Amylase had the widest range of control values.
Pancreatic fluid and elctrolyte outputs were assessed by measurement of duodenal aspirate pH, volume, and bicarbonate content. The maximum pH of duodenal aspirate showed considerable overlap between patients and controls (Fig. 1 ). There were differences in duodenal aspirate volume between control and cystic fibrosis patients. Comparison of volume output per kilogram body weight (Fig. 1B) , showed that all cystic fibrosis patients were below the control range except for patient no. 1 whose volume output was in range but below the 10th percentile. The relationship between volume output and body weight (Fig. 2) appeared to be different in cystic fibrosis patients (y = 0.8x -1.3, p < 0.001, r = 0.84) compared with the controls (y = 3.6x + 6.5, p 0.001, r = 0.88). The non-cystic fibrosis patients (A-E) with abnormal pancreatic function results seemed to follow the same volume/weight relationship as the control group. For any given weight, cystic fibrosis patients, including those with higher enzyme output, had a lower volume of ouput than controls.
Bicarbonate measurement also showed significant differences between cystic fibrosis and controls (Fig.  3) . The maximal bicarbonate concentration in cystic fibrosis patients was below the control range in all but two patients whose results were below the 10th percentile (Fig. 3) . Low We performed the secretin-pancreozymin test using a relatively simple technique in the hope of minimising discomfort to the patient. The tube used was readily passed and easy to aspirate with little tendency to block. The test procedure was generally well tolerated by our patients, though some discomfort remained during passage of the tube. Gastric juice contamination was usually readily apparent by change in pH and turbidity of the aspirate, and could usually be avoided by positioning and by aspiration of the stomach. Our pancreatic enzyme results separate clearly n bicarbonate two groups of cystic fibrosis patients with and t the relation-without adequate pancreatic enzyme function. It ;is (y = 0.001x was interesting to note that the ability to secrete a as compared significant amount of enzyme was not strictly ormalities of familial. In one pair of siblings tested (patients nos.
as (y = 0*002x 9 and 10) both secreted significant amounts of enzymes, but, in the other pair, one had low enzymes (patient 6) and the other had normal enzymes (patient 14 group.bmj.com on April 5, 2017 -Published by http://gut.bmj.com/ Downloaded from differences between cystic fibrosis and non-cystic fibrosis subjects regardless of whether the cystic fibrosis subject was able to secrete measurable amounts of pancreatic enzymes or not. Cystic fibrosis patients appeared to have an altered relationship between volume output and body weight, and between the two main types of pancreatic secretions -that is, between enzyme and bicarbonate output. These differences, which suggest abnormal fluid and electrolyte transport in the cystic fibrosis pancreas, become most apparent for the individual patient when the rate of output of bicarbonate after pancreatic stimulation is considered. This measurement reflects both the bicarbonate concentration and fluid volume output together, and is probably a more accurate indicator of the functional capacity for fluid and electrolyte secretion of the pancreas than either measurement alone. In our series, this measurement clearly separated cystic fibrosis from non-cystic fibrosis subjects in all cases.
These results seem very promising with regard to the usefulness of the secretin-pancreozymin test in confirming the diagnosis of cystic fibrosis, but a number of factors have to be considered when interpreting them. The problem of completeness of. sample collection arises when considering results based on volume measurements. It may be that markers such as polyethylene glycol and bromsulphalein should be used to assess and correct for incomplete collections or gastric juice contamination. Use of bromsulphalein as marker by one group seemed to suggest that a higher recovery of secretions occurred in cystic fibrosis compared with control patients. 19 If this was the case in our series, our data would relatively underestimate control values, and the true difference between cystic fibrosis and non-cystic fibrosis would be even more marked than we have demonstrated.
The method used to stimulate pancreatic secretion seems also to be important. Our results and those of Hadorn et a12 were obtained using 'standard' single dose stimulation with secretin and pancreozymin, but repeated high dosage or continuous secretin infusions may be capable of increasing bicarbonate secretin by cystic fibrosis patients to levels overlapping those of controls. 3 18 It is possible that these differences in results reflect an analagous situation to that of the sweat test, where valid results depend upon use of a carefully selected and standardised method of sweat stimulation.
Conclusions
Our results support the premise that all cystic fibrosis patients, regardless of their ability to produce pancreatic enzymes, have an abnormality in pancreatic fluid and bicarbonate secretion. This abnormality is most apparent when the rate of bicarbonate output after pancreatic stimulation is compared for cystic fibrosis and non-cystic fibrosis individuals. This measurement appears to be capable of differentiating between these two types of patient.
More work is needed to confirm these results, to assess their diagnostic usefulness, and to establish the optimal conditions of pancreatic stimulation and collection of secretions for this purpose. In the meantime, we feel that careful use of the secretinpancreozymin test, as described here, is warranted whenever there is doubt about the diagnosis of cystic fibrosis, despite a careful clinical assessment and adequately performed sweat testing. 
